Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Dose-Ranging Study for Prolonged Postoperative Analgesia in Subjects Undergoing Primary Unilateral Inguinal Hernia Repair
This study has been completed.
Sponsored by: Pacira Pharmaceuticals, Inc
Information provided by: Pacira Pharmaceuticals, Inc
ClinicalTrials.gov Identifier: NCT00485433
  Purpose

The purpose of this study is to evaluate three dose levels of SKY0402 compared with 105 mg of bupivacaine HCl.


Condition Intervention Phase
Postoperative Pain
Drug: SKY0402
Phase II

MedlinePlus related topics: Hernia
U.S. FDA Resources
Study Type: Interventional
Study Design: Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Phase 2 Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Control, Dose-Ranging Study to Evaluate the Safety and Efficacy of a Single Administration of SKY0402 for Prolonged Postoperative Analgesia in Subjects Undergoing Primary Unilateral Inguinal Hernia Repair.

Further study details as provided by Pacira Pharmaceuticals, Inc:

Primary Outcome Measures:
  • Evaluate 3 dose levels of SKY0402 compared with bupivacaine HCl, with respect to extent and duration of analgesic effect [ Time Frame: Up to 30 days ]

Secondary Outcome Measures:
  • Select a therapeutic dose; Identify a dose less effective than the selected therapeutic dose; Evaluate additional efficacy parameters; Characterize the safety profile of SKY0402 in comparison to bupivacaine HCl [ Time Frame: Up to 30 days ]

Estimated Enrollment: 100
Study Start Date: June 2007
Study Completion Date: August 2008
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Detailed Description:

Effective postoperative pain control is a critical element in patient recovery, as the majority of patients may experience significant pain, particularly in the first few days following surgery. Appropriate postoperative pain management contributes to improved healing, faster patient mobilization, shortened hospital stays, and reduced healthcare costs.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Males 18 years of age and older at the Screening Visit.
  2. Scheduled to undergo, elective, primary, unilateral, open-technique, tension-free (Lichtenstein-type technique with mesh)inguinal hernia repair under general anesthesia.
  3. American Society of Anesthesiology (ASA) Physical Class 1-3.
  4. Capable and willing to comply with all study visits and procedures and to provide written informed consent.
  5. Able to speak, read, and understand the language of the Informed Consent, study questionnaires, and other instruments used for collecting subject-reported outcomes, in order to enable accurate and appropriate responses to pain scales and other required study assessments.

Exclusion Criteria:

  1. Use of any of the following medications within the times specified before surgery:

    • Long-acting opioid medication within 3 days.
    • Any opioid medication within 24 hours.
  2. Concurrent painful physical condition that may require analgesic treatment in the postoperative period for pain that is not strictly related to the hernia repair procedure and may confound the postoperative assessments (e.g., rheumatoid arthritis, neuropathic pain, concomitant vasectomy).
  3. Body weight less than 50 kilograms.
  4. History of hypersensitivity or idiosyncratic reaction to amide-type local anesthetics.
  5. Other contraindication to bupivacaine.
  6. Contraindication(s) to epinephrine, such as concurrent administration of monoamine oxidase (MAO) inhibitors or antidepressants of amitriptyline or imipramine types, conditions where the production or exacerbation of tachycardia could prove fatal (e.g., poorly controlled thyrotoxicosis or severe heart disease), or any other pathological conditions that might be aggravated by the effects of epinephrine.
  7. Contraindication to any of the pain control agents anticipated to be used postoperatively (i.e., acetaminophen or oxycodone).
  8. Administration of an investigational product within 30 days or 5 elimination half-lives of such investigational product, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study.
  9. Suspected or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years.
  10. Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the Investigator, may interfere with study assessments or compliance.
  11. Current or historical evidence of any clinically significant condition that, in the opinion of the Investigator, may increase the risk of surgery, complicate the subject's postoperative course, or indicate an increased vulnerability to study drugs and procedures and expose the subject to an unreasonable risk as a result of participating in this clinical trial.

    If during surgery the following criterion is met:

  12. Any clinically significant event or condition uncovered during the hernia repair surgery (e.g., excessive bleeding) that might render the subject medically unstable or complicate the subject's postoperative course.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00485433

Locations
United States, California
Huntington Memorial Hospital
Pasadena, California, United States, 91105
Arcadia Methodist Hospital
Arcadia, California, United States, 91007
Saddleback Valley Outpatient Surgery
Laguna Hills, California, United States, 92653
United States, New York
St. Luke's Roosevelt Hosptial Center
New York, New York, United States, 10025
United States, Pennsylvania
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States, 19107
United States, Texas
Kirby Outpatient Surgical Center
Houston, Texas, United States, 77054
Memorial Hermann Healthcare System
Houston, Texas, United States, 77024
Sponsors and Collaborators
Pacira Pharmaceuticals, Inc
  More Information

Responsible Party: Pacira Pharmaceuticals, Inc. ( Marius Ardeleanu, MD / Medical Monitor )
Study ID Numbers: SKY0402C207
Study First Received: June 11, 2007
Last Updated: August 25, 2008
ClinicalTrials.gov Identifier: NCT00485433  
Health Authority: United States: Food and Drug Administration

Keywords provided by Pacira Pharmaceuticals, Inc:
hernia
unilateral
postoperative
analgesia

Study placed in the following topic categories:
Pathological Conditions, Anatomical
Signs and Symptoms
Postoperative Complications
Hernia
Hernia, Abdominal
Pain
Hernia, Inguinal
Pain, Postoperative

Additional relevant MeSH terms:
Pathologic Processes

ClinicalTrials.gov processed this record on January 16, 2009